



# **SURGICAL PATHOLOGY REPORT** **\* Revised Report \***

Patient Name: [REDACTED]  
Med. Rec. #: [REDACTED]  
DOB/Gender: [REDACTED] (Age: F  
Location: [REDACTED]  
Sec. Sec. #: [REDACTED]  
Physician(s): [REDACTED]

Path No.: [REDACTED]  
Client: [REDACTED]  
Collected: [REDACTED]  
Received: [REDACTED]  
Reported: [REDACTED]  
Hosp #: [REDACTED]

## **Pre-Operative/Clinical History**

THIS IS A REVISED REPORT

Endometrial cancer

## **Specimen(s) Received**

- A: RIGHT ADNEXA
- B: UTERUS WITH CERVIX
- C: BIOPSY, OMENTUM
- D: LEFT ADNEXA
- E: RIGHT PELVIC LYMPH NODE BIOPSY

Criteria	Yes	No
Diagnosis Discrepancy		
Primary Tumor Site Discrepancy		
HIPAA Discrepancy		
Prior Malignancy History		
Dual/Synchronous Primary Noted		
Case (circle):	QUALIFIED	DISQUALIFIED
Reviewer (circle):	10/25/11	10/25/11

ICD-0-3

adenocarcinoma, endometrioid, NOS 8380/3  
site: Endometrium C54.1  
10/25/11

## **Gross Description**

Specimen A, received fresh for frozen section labeled right adnexa.

Ovary:

Size: 7.0 x 4.5 x 4.0 cm, 40 gm.

Description: The ovary is approximately up to 3.0 cm in greatest dimension with a bulging nodule that is up to 4.8 cm in greatest dimension and shows a pink smooth surface with petechial hemorrhage. On sectioning, the ovary is predominantly replaced by a unilocular cyst that is 2.5 cm in greatest dimension. The nodule shows a whorled tan rubbery cut surface. A section is sampled for frozen section in (A1FS).

Fallopian Tube:

Size: 4.0 cm in length by 0.5 cm in diameter.

Description: Fimbriated. The serosa is pink-tan, glistening and intact.

Representative sections as follows:

- (A1FS) Frozen section resubmitted
- (A2) Fallopian tube
- (A3, 4) Ovary including cyst
- (A5, 6) Nodule.

Specimen B, received fresh for an OR consultation labeled uterus with cervix.

Specimen type: Uterus with attached cervix.

Procedure: Hysterectomy.

Specimen Integrity: Intact.

## HISTOLOGY REPORT

**Weight:** 161 gm.

**Measurement:** 9.5 cm ectocervix to fundus x 6.8 cm cornu to cornu x 4.0 cm anterior to posterior.

**Serosa:** Pink-tan and glistening with a bulging subserosal nodule that is up to 2.4 cm and is markedly calcified.

**Cervix:**  
    **Measurement:** 2.4 x 1.5 cm.  
    **Description:** The cervix shows a probe patent ectocervical os surrounded by pink glistening ectocervical mucosa with a scant amount of petechial hemorrhage. Sectioning the cervix is grossly unremarkable.  
    **Involved/Not involved:** Not involved.

**Tumor site:** Endometrium.

**Tumor size:** 4.0 x 4.0 cm with a maximum thickness of 0.7 cm.

**Tumor description:** The tumor shows a pink papillary to friable appearance with a small amount of adherent clotted blood. The tumor is grossly confined to the upper half of the myometrium, grossly comes to within 3.8 cm of the ectocervical os and 1.3 cm of the closest posterior (black) serosa.

**Endometrium:**  
    **Thickness:** 0.9 cm.  
    **Description:** The remaining approximately 5% of uninvolved endometrium is pink-tan and glistening and is predominantly towards the lower uterine segment.  
    **Involved/Not involved:** Involved.

**Myometrium:**  
    **Thickness:** 2.0 cm.  
    **Description:** Trabeculated with few well-circumscribed intramural nodules, the largest up to 2.5 cm in greatest dimension all with a whorled tan rubbery cut surface most of which are markedly calcified.  
    **Involved/Not involved:** Involved, grossly confined to the upper half of the myometrium.

**Ovary, right:** Not present.

**Fallopian tube, right:** Not present.

**Ovary, left:** Not present.

**Fallopian tube, left:** Not present.

**Other organs present:** None.

A digital photo is taken.

Representative sections are as follows:

(B1)	Serosa
(B2, 3)	Anterior cervix and lower uterine segment, slice bisected
(B4)	Anterior cervix
(B5, 6)	Posterior cervix and lower uterine segment, slice bisected
(B7)	Posterior cervix
(B8-11)	Anterior endomyometrium full thickness section including tumor with deepest point of invasion
(B12-15)	Posterior endomyometrium including tumor full thickness section including deepest point of invasion
(B16)	Representative section of partially calcified intramural nodules following light decalcification.

## HISTOLOGY REPORT

Specimen C, received in formalin labeled biopsy omentum, consists of a 2.5 x 1.7 x 1.8 cm portion of lobular adipose tissue. The specimen is sectioned and entirely submitted in (C1 ).

Specimen D, received in formalin labeled left adnexa, consists of:

**Ovary:**

Size: 2.4 x 1.3 x 1.0 cm, 2 gm.

Description: The outer surface is smooth. Sectioning shows a 0.5 cm simple cyst filled with clear fluid.

**Fallopian Tube:**

Size: 4.0 cm in length by 0.5 cm in diameter.

Description: Fimbriated. The serosa is pink-tan, glistening and intact.

Representative sections as follows:

(D1) Fallopian tube

(D2) Ovary.

Specimen E, received in formalin labeled biopsy, right pelvic lymph node, consists of a 0.7 x 0.3 x 0.3 cm yellow-pink, glistening, rubbery tissue fragment. The specimen is bisected and entirely submitted in (E1 ).

### Intraoperative Consultation

Specimen A, frozen section diagnosis of "fibroma" is rendered by Dr.

An OR consultation is performed on specimen B: "at least superficial myometrial invasion" is rendered by Dr. I

### Microscopic Description

#### Summary of Pathologic Findings Endometrial Carcinoma

**Procedure:** Abdominal hysterectomy with bilateral salpingo-oophorectomy.

**Lymph node sampling:** Performed, pelvic.

**Histologic type:** Endometrioid adenocarcinoma with clear cell differentiation.

**FIGO grade (I-III):** III.

**Myometrial Invasion:**

Present, tumor invades 11 mm of full 16 mm myometrial thickness, > 50%.

**Uterine serosal involvement:** Absent.

**Cervical/endocervical involvement:** Absent (extends to the lower uterine segment).

**Local/regional extra-uterine tumor direct extension or metastases:** Absent.

**Lymphatic/vascular invasion:** Present.

**Resection margins:** Not involved.

clear cell  
c 10% per TSS. /w

## HISTOLOGY REPORT

### Regional lymph nodes:

Right pelvic lymph node:	1
No. involved:	0
Total nodes examined:	1
No. with tumor:	0.

Distant metastasis: Cannot assess.

### Pathologic stage:

TNM:	pT1b	pN0.
FIGO:	IB.	

Additional pathologic findings: Right ovarian fibroma.  
Right ovarian serous adenofibroma.

The following immunohistochemical stains are performed on the endometrial carcinoma:

Estrogen receptor	Positive
Progesterone receptor	Negative
Cytokeratin AE1/AE3	Positive
WT-1	Negative
P16	Patchy positivity
P53	Negative.

The above immunohistochemical profile is consistent with endometrioid differentiation.

## Diagnosis

### RIGHT OVARY:

FIBROMA.  
SEROUS ADENOFIBROMA.

### LEFT OVARY:

CYSTIC FOLLICLES.

### RIGHT AND LEFT FALLOPIAN TUBES:

NO PATHOLOGIC DIAGNOSIS.

### UTERUS, HYSTERECTOMY:

#### ENDOMETRIUM:

POORLY DIFFERENTIATED ENDOMETRIOID ADENOCARCINOMA WITH CLEAR CELL DIFFERENTIATION.

#### MYOMETRIUM:

TUMOR INVADES FOCALLY GREATER THAN 50%.  
LEIOMYOMAS WITH CALCIFICATION.

#### CERVIX:

NO PATHOLOGIC DIAGNOSIS.

### OMENTUM:

NO TUMOR IDENTIFIED.

### RIGHT PELVIC LYMPH NODE (1):

NO TUMOR IDENTIFIED.

## HISTOLOGY REPORT

\*\*\*Electronically Reviewed and Signed Out By

on

### Comment

Positive and negative controls react satisfactorily.

FDA required disclaimer: These tests were developed and their performance characteristics determined by or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

required information for predictive/prognostic markers: 1. Type of specimen fixation and detection system: Tissue is fixed in 10% formalin. Indirect biotin-free detection kit is used. 2. Clones used: ER (clone 6F11) Novocastra; PR (clone PGR 636) DakoCytomation; CD117 (polyclonal, DakoCytomation); HER2 (clone 4B5, Ventana, FDA approved); KI-67 (clone K3, Cell Marque) p53 (clone DO7, Novocastra), MSH6 (clone BC-44, Biocare), MSH2 (CellMarque clone G219-1129), MLH1 (Cell Marque clone G168-728), PMS2 (clone MRQ-28, Cell Marque). 3. Criteria for positive results: ER and PR:  $\geq 1\%$  of tumor cells with nuclear staining; HER2:  $>30\%$  of cells show complete membrane staining; p53:  $\geq 10\%$  of tumor cells with nuclear staining; MMR Proteins: complete absence of tumor nuclear staining.

### CPT Code(s)

A:  
B:  
C:  
E:

### Amendments

Amended:  
Previous Signout Date: